Advertisement

In an effort to reduce the small but real risk of stent thrombosis associated with drug-eluting stents, stent makers have turned to devices whose polymer or scaffolding dissolves over time.

A series of studies reported at the Transcatheter Cardiovascular Therapeutics (TCT) meeting highlighted the latest results from bioabsorbable devices.

DESSOLVE II

The MiStent sirolimus-eluting biodegradable polymer stent (Micell Technologies) had a mean 0.27 mm late lumen loss at 9 months compared with 0.58 mm for the Endeavor zotarolimus-eluting durable polymer stent (Medtronic) (P<0.001 for superiority), according to David E. Kandzari, MD, of the Piedmont Heart Institute in Atlanta, and colleagues

Continue reading...

Advertisement
Advertisement